

PATENT
Attorney Docket No. CASE-02138

IN THE CLAIMS:

Please cancel Claim 2.

Please amend the Claims as follows:

1. (amended) A method of monitoring immunization, comprising:
 - a) providing: i) a human, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines; and
 - d) determining if said T cells are primarily Th2 cells secreting an anti-inflammatory cytokine or primarily Th1 cells secreting an inflammatory cytokine, wherein said Th2 cells secreting an anti-inflammatory cytokine indicates that said immunizing is protective against multiple sclerosis.

25. (amended) A method of monitoring immunization, comprising:
 - a) providing: i) a human with symptoms of multiple sclerosis, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines; and
 - d) determining if said T cells are primarily Th2 cells secreting an anti-inflammatory cytokine or primarily Th1 cells secreting an inflammatory cytokine, wherein said Th2 cells secreting an anti-inflammatory cytokine indicates that said immunizing is effective for treating symptoms of multiple sclerosis.

PATENT
Attorney Docket No. CASE-02138

Please add the following new claims:

26. (new) A method of monitoring immunization, comprising:
- a) providing: i) a human, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines;
 - d) adding said primary cell population to a microwell comprising a hydrophobic membrane having a first cytokine binding ligand, under conditions such that said T cell secretes a cytokine that binds to said first cytokine binding ligand;
 - e) adding a second cytokine binding ligand to said microwell under conditions such that said cytokine binding ligand binds to said cytokine; and
 - f) detecting said secreted cytokine, thereby monitoring said immunizing.
27. (new) The method of Claim 26, wherein said detected cytokine is IL-5.
28. (new) The method of Claim 26, wherein said detected cytokine is IL-4.
29. (new) The method of Claim 26, wherein said detected cytokine is IL-10.
30. (new) The method of Claim 26, wherein said detected cytokine is IFN γ .
31. (new) The method of Claim 26, wherein said detected cytokine is IL-2.
32. (new) The method of Claim 26, wherein said hydrophobic membrane comprises polyvinylidene difluoride.
33. (new) The method of Claim 26, wherein said microwell comprises an enclosed bottom.

PATENT
Attorney Docket No. **CASE-02138**

34. (new) The method of Claim 1, wherein said determining comprises detecting said secreted cytokine.

35. (new) The method of Claim 1, wherein said secreted cytokine is IL-5.

36. (new) The method of Claim 1, wherein said secreted cytokine is IL-4.

37. (new) The method of Claim 1, wherein said secreted cytokine is IL-10.

38. (new) The method of Claim 1, wherein said secreted cytokine is IFN γ .

39. (new) The method of Claim 1, wherein said secreted cytokine is IL-2.

40. (new) The method of Claim 25, wherein said determining comprises detecting said secreted cytokine.

41. (new) The method of Claim 25, wherein said secreted cytokine is IL-5.

42. (new) The method of Claim 25, wherein said secreted cytokine is IL-4.

43. (new) The method of Claim 25, wherein said secreted cytokine is IL-10.

44. (new) The method of Claim 25, wherein said secreted cytokine is IFN γ .

45. (new) The method of Claim 25, wherein said secreted cytokine is IL-2.